An overview of the regulation of influenza vaccines in the United States

Influenza and other Respiratory Viruses

Volumn 10, Issue 5, 2016, Pages 354-360

  Weir, Jerry P ^a   Gruber, Marion F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

influenza vaccines; vaccine licensing; vaccine regulation

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VIRUS; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; UNITED STATES;

EID: 84978706218     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12383     Document Type: Article

References (26)

1. Fiore AE, Bridges CB, Katz JM, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, (eds): Vaccines. Sixth edn: Elsevier; 2013. p. 257–293.
2. Plotkin SL, Plotkin SA. A Short History of Vaccination. In: Plotkin SA, Orenstein WA, Offit PA (eds): Vaccines. 6th edn: Elsevier; 2013. p. 1–13.
3. FDA. clinical data needed to support the licensure of seasonal inactivated influenza vaccines: Guidance for Industry. US Food and Drug Administration, 2007. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm.
4. Ampofo WK, Baylor N, Cobey S et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses 2011; 6:142–152.
5. Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010; 28:2442–2449.
6. Robertson JS. Sequence analysis of the haemagglutinin of A/Taiwan/1/86, a new variant of human influenza A(H1N1) virus. J Gen Virol 1987; 68:1205–1208.
7. CDC. Monovalent influenza A(H1N1) vaccine, 1986-1987. Recommendations of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services. Ann Intern Med 1986; 105:737–739.
8. Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014; 6:234ra55.
9. Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 2012; 7:e49704.
10. Langley JM, Risi G, Caldwell M et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:1729–1738.
11. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343–1351.
12. FDA. Clinical data needed to support the licensure of pandemic influenza vaccines. Guidance for Industry. US Food and Drug Administration, 2007; http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm
13. Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461–2473.
14. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175:59–68.
15. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8:81–88.
16. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28(Suppl 4):D45–D53.
17. Manini I, Domnich A, Amicizia D et al. Flucelvax (Optaflu) for seasonal influenza. Expert Rev Vaccines 2015; 14:789–804.
18. Buckland B, Boulanger R, Fino M et al. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine 2014; 32:5496–5502.
19. Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013; 369:2564–2566.
20. Taylor DN, Treanor JJ, Sheldon EA et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012; 30:5761–5769.
21. Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y. Adjuvanted influenza vaccines. Expert Rev Vaccines 2013; 12:1095–1108.
22. Tsai TF. Fluad(R)-MF59(R)-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother 2013; 45:159–174.
23. Ampofo WK, Al Busaidy S, Cox NJ et al. Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conferences (CICG) Geneva, Switzerland, 7 to 9 December 2011. Vaccine 2013; 31:3209–3221.
24. Ampofo WK, Azziz-Baumgartner E, Bashir U et al. Strengthening the influenza vaccine virus selection and development process: report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine 2015; 33:4368–4382.
25. Dormitzer PR, Suphaphiphat P, Gibson DG et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013; 5:185ra68.
26. Ping J, Lopes TJ, Nidom CA et al. Development of high-yield influenza A virus vaccine viruses. Nat Commun 2015; 6:8148.